Production of immunogenic human papillomavirus-16 major capsid protein derived virus like particles

Indian Journal of Medical Research

Volumn 130, Issue 3, 2009, Pages 213-218

  Patel, Mira C ^a   Patkar, Ketaki K ^b   Basu, Atanu ^c   Mohandas, K M ^d   Mukhopadhyaya, Robin ^b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b CANCER RESEARCH INSTITUTE   (India)

^c NATIONAL INSTITUTE OF VIROLOGY   (India)

^d TATA MEMORIAL HOSPITAL   (India)

Author keywords

Human papillomavirus type 16; Major capsid protein; Recombinant protein expression; VLP; Yeast expression system

Indexed keywords

GALACTOSE; GENOMIC DNA; IMMUNOGLOBULIN G; RECOMBINANT CAPSID PROTEIN L1; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY TITER; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CANCER; GENE AMPLIFICATION; GENE EXPRESSION SYSTEM; HETEROLOGOUS EXPRESSION; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOREACTIVITY; MOLECULAR CLONING; MOLECULAR WEIGHT; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; RECOMBINANT DNA TECHNOLOGY; REVIEW; SACCHAROMYCES CEREVISIAE; TRANSMISSION ELECTRON MICROSCOPY; TUMOR BIOPSY; VACCINE PRODUCTION; VIRUS LIKE AGENT;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMAN PAPILLOMAVIRUS 16; HUMANS; ONCOGENE PROTEINS, VIRAL; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE;

EID: 72649094063     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. IARC monographs on the evaluation of carcinogenic risks to humans: Hum papillomaviruses, vol. 90. Lyon, France: IARC; 2007. p. 179-327.
2. Nood R, Roy P. Virus-like particles as immunogens. Trends Microbiol 2003; 11: 438-44.
3. Pattenden LK, Middelberg APJ, Niebert M, Lipin DI. Towards the preparative and large-scale precision manufacture of virus- like particles. Trends Biotechnol 2006; 23: 524-9.
4. Banks L, Matlashewski G, Pim D, Churcher M, Roberts C, Crawford L. Expression of human papillomavirus type 6 and type 16 capsid proteins in bacteria and their antigenic characterization. J Gen Virol 1987; 68: 3081-9.
5. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci (USA) 1992; 89: 12180-4.
6. Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L, et al. Efficient self-assembly of Human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993; 67: 6929-36.
7. Neeper MP, Hofmann KJ, Jansen KU. Expression of the major capsid protein of human papillomavirus type 11 in Saccharomyces cerevisae. Gene 1996; 180: 1-6.
8. Zhang W, Carmichael J, Ferguson J, Inglis S, Ashrafian H, Stanley M. Expression of Human papillomavirus type 16 L1 protein in Escherichia coli: Denaturation, renaturation, and self-assembly of virus-like particles in vitro. Virology 1998; 243: 423-31.
9. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT. A virus-like particles enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 1994; 86: 494-9.
10. Park J, Pyo H, Yoon S, Baek S, Park S, Kim C, et al. Production and prophylactic efficacy study of human papillomavirus-like particle expressing HPV16 L1 capsid protein. J Microbiol 2002; 40: 313-8.
11. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, et al. Comparison of Human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181: 1911-9.
12. Christianson TW, Sikorski RS, Dante M, Shero JH, Hieter P. Multifunctional yeast high-copy-number shuttle vectors. Gene 1992; 110: 119-22.
13. Sikorski RS, Hieter P. A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics 1989; 122: 19-27.
14. Cook JC, Joyce JG, George HA, Schultz LD, Hurni WM, Jansen KU, et al. Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae. Protein Expr Purif 1999; 17: 477-84.
15. Kim SN, Jeong HS, Park SN, Kim HJ. Purification and immunogenicity study of human papillomavirus type 16 L1 protein in Saccharomyces cerevisiae. J Virol Methods 2007; 139: 24-30.
16. Park MA, Kim HJ, Kim HJ. Optimum conditions for production and purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae. Protein Expr Purif 2008; 59: 175-81.
17. Harro CD, Pang YS, Roden RBS, Hildesheim A, Wang Z, Reynolds MJ, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001; 93: 284-92.
18. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-51.
19. Villa LA, Costa RLR, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-8.
20. Stanley M, Lowy DR, Frazer I. Prophylactic HPV vaccines: Underlying mechanisms. Vaccine 2006; 24 (Suppl) 3: S106-13.